| Literature DB >> 29516015 |
Omid Nikoubashman1, Kolja Schürmann2, Ahmed E Othman3, Jan-Philipp Bach2, Martin Wiesmann1, Arno Reich2.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2018 PMID: 29516015 PMCID: PMC5817218 DOI: 10.1155/2018/9548743
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Schematic illustration of preinterventional workflow in our institution. RCC: rescue coordination centre; N: neurologist; NR: neuroradiologist; AN: anaesthesiologist; SU/NICU: stroke unit/neurological intensive care unit; CT: computed tomography; cCT: cranial CT; CTA: CT angiography; CTP: CT perfusion; ICH: intracranial/intracerebral haemorrhage; LVO: large vessel occlusion; IVRTPA: systemic thrombolysis; EST: endovascular stroke treatment. Dotted lines: phone calls. After the neurologist in charge is informed about a possible stroke by the rescue coordination centre, the neurologist informs the neuroradiologist in charge about the case. If a short clinical examination confirms the stroke, the anaesthesiologist on call is also informed and the patient is transferred to the CT suite, where the extent of stroke is assessed and an unenhanced CT is performed. In the meantime, the stroke unit or neurological intensive care unit is informed about the case. If there is no haemorrhage, and the patient fulfils standard inclusion criteria for thrombolysis, systemic thrombolysis is administered and a CT angiography is performed. If there is occlusion of a large cerebral artery, the interventionalist and the anaesthesiologist are informed and the patient is transferred to the angiography suite. In the angiography suite, there is parallel workflow with the interventionalist performing the groin puncture, while the anaesthesiologist intubates the patient.
Figure 2“Stroke Check” form for interdisciplinary documentation of treatment related data. Initial NIHSS scores and follow-up mRS are documented on the back of the sheet.
Figure 3Boxplots illustrating procedural times. Outliers are not illustrated. Phase 0: before establishing a 24 h neuroradiological on-site service in May 2012. Phase 1: after introduction of a 24 h neuroradiological on-site service but before workflow optimization with extensive documentation of procedural times in February 2014. Phase 3: after workflow optimization with extensive documentation of procedural times.
Overview of included patients. Phase 0: before establishing a 24 h neuroradiological on-site service in May 2012. Phase 1: after introduction of a 24 h neuroradiological on-site service but before workflow optimization with extensive documentation of procedural times in February 2014. Phase 2: after workflow optimization with extensive documentation of procedural times. NIHSS: national institute for health stroke scale; mRS: modified Rankin scale; ASPECTS Alberta stroke program early CT score. ICA: internal carotid artery; MCA: middle cerebral artery; ACA: anterior cerebral artery; VA: vertebral artery; BA: basilar artery; PCA: posterior cerebral artery. IA: intra-arterial. EST: endovascular stroke treatment. Values expressed as means ± standard deviation if not indicated otherwise.
| Phase 0 | Phase 1 | Phase 2 |
| |
|---|---|---|---|---|
| Demographics | ||||
| Age (yr) ( | 69.8 ± 15.7 (median, 72.9; IQR, 16.5) | 71.5 ± 12.7 (median, 72.1 IQR, 18.1) | 70.4 ± 14.2 (median, 72.9; IQR, 16.7) | 0.673 |
| Male sex ( | 52 (54.2%) | 63 (50.0%) | 43 (43.0%) | 0.284 |
|
| ||||
| Medical history | ||||
| Hypertension ( | 69 (71.9%) | 100 (79.4%) | 83 (82.0%) | 0.156 |
| Diabetes ( | 26 (27.1%) | 22 (17.5%) | 35 (35.0%) | 0.011 |
| Fat metabolism disorder ( | 36 (37.5%) | 38 (30.2%) | 23 (23.0%) | 0.087 |
| Adiposity ( | 31 (32.3%) | 30 (23.8%) | 21 (21.0%) | 0.166 |
| Nicotine ( | 22 (22.9%) | 35 (27.8%) | 20 (20.0%) | 0.381 |
| Cardiovascular disease ( | 49 (51.0%) | 69 (54.8%) | 29 (29.0%) | <0.001 |
| Atrial fibrillation ( | 47 (49.0%) | 61 (48.4%) | 51 (51.0%) | 0.924 |
| Prior stroke ( | 16 (16.7%) | 23 (18.3%) | 19 (19.0%) | 0.910 |
| Current antiplatelet use ( | 26/93 (28.0%) | 34/121 (28.1%) | 27/82 (32.9%) | 0.711 |
| Current anticoagulant use ( | 8 (8.3%) | 16 (12.7%) | 16 (16.0%) | 0.264 |
|
| ||||
| Clinical baseline | ||||
| NIHSS on admission | 17.6 ± 7.0 (median, 17.0; IQR, 8) | 17.9 ± 7.2 (median, 18.0; IQR, 6) | 17.6 ± 5.5 (median, 19.0; IQR, 3) | 0.935 |
| mRS on admission | 4.6 ± 0.6 (median, 5.0; IQR, 1) | 4.5 ± 0.7 (median, 5.0; IQR, 1) | 4.5 ± 0.6 (median, 5.0; IQR, 1) | 0.734 |
|
| ||||
| Site of vessel occlusion | ||||
| Anterior circulation (ICA, MCA, ACA) ( | 81 (84.4%) | 108 (85.7%) | 86 (86.0%) | 0.942 |
| Posterior circulation (VA, BA, PCA) ( | 15 (15.6%) | 18 (14.3%) | 14 (14.0%) | |
| Initial ASPECT score | 9.0 ± 1.4 (median, 10.0; IQR, 2) | 8.9 ± 1.6 (median, 9.5; IQR, 1) | 7.6 ± 3.4 (median, 9.0; IQR, 4) | <0.001 |
|
| ||||
|
| ||||
| Onset to door (min) | 89.7 ± 92.5 (median, 61.0; IQR, 50) | 111.3 ± 76.8 (median, 95.0; IQR, 92) | 96.9 ± 63.8 (median, 79.5; IQR, 73) | 0.247 |
| Door to image (min) | 30.6 ± 15.9 (median, 27.0; IQR, 12) | 27.81 ± 9.9 (median, 28.0; IQR, 12) | 24.0 ± 11.2 (median, 22.0; IQR, 10) | 0.001 |
| Image to puncture (min) | 66.4 ± 34.0 (median, 60.0; IQR, 33) | 56.8 ± 22.3 (median, 53.0; IQR, 55) | 47.6 ± 18.6 (median, 46.0; IQR, 23) | <0.001 |
| Puncture to revascularization (min) | 87.0 ± 58.9 (median, 64.5; IQR, 68) | 77.9 ± 46.2 (median, 67.5; IQR, 62) | 71.5 ± 49.9 (median, 54.5; IQR, 55) | 0.100 |
| Door to revascularization (min) | 188.5 ± 84.4 (median, 171.0; IQR, 86) | 162.4 ± 52.6 (median, 156.0; IQR, 72) | 150.4 ± 71.8 (median, 129.0; IQR, 66) | 0.001 |
| Onset to revascularization (min) | 268.0 ± 116.2 (median, 233.5; IQR,121) | 265.8 ± 97.8 (median, 254.5; IQR, 106) | 239.6 ± 91.1 (median, 216.0; IQR, 118) | 0.244 |
|
| ||||
|
| ||||
| Systemic thrombolysis ( | 69 (71.9%) | 87 (69.0%) | 67 (67.0%) | 0.759 |
| IA thrombolysis ( | 34 (35.4%) | 28 (22.2%) | 9 (9.0%) | <0.001 |
| Stent retriever ( | 77 (80.2%) | 118 (93.7%) | 97 (97.0%) | <0.001 |
|
| ||||
| Outcome | ||||
| Successful revascularization (TICI ≥ 2b) ( | 80 (83.3%) | 104 (82.5%) | 86 (86.0%) | 0.771 |
| Good clinical outcome (mRS ≤ 2 d90) ( | 31/79 (39.2%) | 34/114 (29.8%) | 18/78 (23.1%) | 0.087 |
| Death (d90) ( | 24/79 (30.4%) | 38/114 (33.3%) | 29/78 (37.2%) | 0.664 |
p values < 0.05 were considered significant.